Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical imiquimod versus DPCP for cutaneous in-transit melanoma metastases
ACTRN12615001088538Phase 2Recruiting
- Sponsor
- Professor B Mark Smithers
- Start
- Jan 2017
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of imiquimod and diphencyprone in melanoma (3 arms), sponsored by Professor B Mark Smithers. Primary endpoint: Complete clinical response in treated lesions. Started Jan 2017; status: recruiting.
02
Drugs
imiquimoddiphencyprone
03
Conditions
melanoma
Beyond the preview
Go deeper on ACTRN12615001088538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615001088538.